NOMO2: A Potential Drug Target for Various Diseases (G283820)

Target Name: NOMO2

NCBI ID: G283820

NOMO2

NOMO2: A Potential Drug Target for Various Diseases

NOMO2, or Nodal modulator 2, is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It is a key regulator of cell proliferation and has been implicated in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a drug target, NOMO2 is a promising target for the development of new treatments for these diseases.

The NODAL modulator 2 (NOMO2) gene is located on chromosome 18q21 and encodes a protein that is expressed in various tissues throughout the body. NOMO2 is a key regulator of cell proliferation and has been implicated in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the key functions of NOMO2 is its role as a negative regulator of the G1/S transition. The G1/S transition is a critical step in the cell cycle that marks the beginning of the S phase, where the cell prepares for cell division. NOMO2 plays a key role in regulating the G1/S transition by preventing the G1 checkpoint from being activated. This checkpoint is important for ensuring that the cell has completed all of its necessary tasks before it begins to divide, and NOMO2's inhibition of the G1 checkpoint has been linked to the development of cancer.

In addition to its role in cell proliferation, NOMO2 has also been shown to play a key role in the regulation of neurodegenerative diseases. neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases, are characterized by the progressive loss of brain cells and are often associated with increased levels of NOMO2 in the brain.

NOMO2 has also been shown to play a key role in the regulation of autoimmune disorders. autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis, are characterized by the immune system attacking the body's own tissues. NOMO2 has been shown to play a key role in the regulation of immune cell function and has been implicated in the development of these disorders.

Despite the potential for NOMO2 as a drug target, much research is still needed to fully understand its functions and the potential for its use in treating these diseases. Currently, there are no approved drugs that target NOMO2. Researchers are actively working to develop new treatments for NOMO2-related diseases and to understand more about its potential as a drug target.

In conclusion, NOMO2 is a protein that plays a critical role in the regulation of cell proliferation and has been implicated in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a drug target, NOMO2 is a promising target for the development of new treatments for these diseases. Further research is needed to fully understand its functions and potential as a drug target.

Protein Name: NODAL Modulator 2

Functions: Component of the multi-pass translocon (MPT) complex that mediates insertion of multi-pass membrane proteins into the lipid bilayer of membranes (PubMed:36261522, PubMed:32820719). The MPT complex takes over after the SEC61 complex: following membrane insertion of the first few transmembrane segments of proteins by the SEC61 complex, the MPT complex occludes the lateral gate of the SEC61 complex to promote insertion of subsequent transmembrane regions (PubMed:36261522)

The "NOMO2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NOMO2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets